Changes in the expression of CD62L and CCR7 on CD123^hiBDCs after G-CSF or CY/G-CSF treatment.

CD62L and CCR7 were analyzed on CD123^hiBDCs in steady state (SS, prior to commencement of the PBSC mobilization protocol) and on the day of apheresis (DA). Data from individual healthy donors, MM, and NHL patients are represented. Open and filled symbols indicate therapy including low- and high-dose G-CSF, respectively, and correspond to the symbols in Figure 1 and Table 1.